First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

Background: Targeting factor XI (FXI) is a promising therapeutic strategy for the treatment and prevention of thrombosis without increasing the risk of bleeding. Here, we assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR2285, a novel FXIa inhibitor, in healthy subjects. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Guan, Xiaoduo, Hu, Pei, Dong, Yanli, Zhu, Yi, Zhang, Tengfei, Zou, Jianjun, Zhang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866703/
https://www.ncbi.nlm.nih.gov/pubmed/35222036
http://dx.doi.org/10.3389/fphar.2022.821363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866703/
https://www.ncbi.nlm.nih.gov/pubmed/35222036
http://dx.doi.org/10.3389/fphar.2022.821363

Ejemplares similares